Metis Global Partners, LLC Mannkind Corp Transaction History
Metis Global Partners, LLC
- $3.16 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding MNKD
# of Institutions
245Shares Held
148MCall Options Held
1.62MPut Options Held
802K-
Black Rock Inc. New York, NY22.6MShares$154 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.6MShares$107 Million0.0% of portfolio
-
State Street Corp Boston, MA9.6MShares$65.6 Million0.0% of portfolio
-
Nitorum Capital, L.P. New York, NY9.16MShares$62.6 Million6.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.75MShares$59.9 Million0.83% of portfolio
About MANNKIND CORP
- Ticker MNKD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 257,338,000
- Market Cap $1.76B
- Description
- MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...